|
Sign In to gain access to subscriptions and/or personal tools.
|
Commentary: Discovery Toxicology—A Nascent Science
Bruce D. Car
Safety Assessment, Preclinical Research and Development, DuPont Pharmaceuticals, Newark, Delaware 19714
Richard T. Robertson
Safety Assessment, Preclinical Research and Development, DuPont Pharmaceuticals, Newark, Delaware 19714
References
- Coogan AN, O'Leary DM, and O'Conner JJ (1999). P42/44 MAP kinase inhibitor PD98059 attenuates multiple forms of synaptic plasticity in rat dentate gyrus in vitro. J Neurophysiol. 81: 103-110.[Abstract/Free Full Text]
- Debouck C. and Goodfellow PN (1999). DNA microarrays in drug discovery and development. Nat. Genet. 21: 48-50.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Foxall PJ and Nicholson JK (1998). Nuclear magnetic resonance spectroscopy: A non-invasive probe of kidney metabolism and function. Exp. Nephrol. 6: 409-414.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kornhauser JM and Greenberg ME (1997). A kinase to remember: Dual roles for MAP kinase in long-term memory [comment]. Neuron 18: 839-842.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mocsai A., Banfi B., Kapus A., Farkas G., Geiszt M., Buday L., Farago A., and Ligeti E. (1997). Differential effects of tyrosine kinase inhibitors and an inhibitor of the mitogen-activated protein kinase cascade on degranulation and superoxide production of human neutrophil granulocytes. Biochem. Pharmacol. 54: 781-789.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Nagata Y., Takahashi N., Davis RJ, and Todokoro K. (1998). Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 92: 1859-1869.[Abstract/Free Full Text]
- Nahas N., Molski TF, Fernandez GA, and Sha'afi RI (1996). Tyrosine phosphorylation and activation of a new mitogen-activated protein (MAP)-kinase cascade in human neutrophils stimulated with various agonists. Biochem. J. 318: 247-253.[Web of Science][Medline]
[Order article via Infotrieve]
- Rudmann DG and Durham SK (1999). Utilization of genetically altered animals in the pharmaceutical industry. Toxicol. Pathol. 27: 111-114.[Abstract/Free Full Text]
- Schnyder B., Meunier PC, and Car BD (1998). Inhibition of kinases impairs neutrophil activation and killing of Staplzylococcus aureus. Biochem. J. 15: 489-495.
- Scriver CR (ed) (1995). The Metabolic and Molecular Bases of Inherited Disease, 7th ed. McGraw-Hill, New York.
- Sui X., Krantz SB, You M., and Zhao Z. ( 1998). Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 92: 1142-1149.[Abstract/Free Full Text]
Toxicologic Pathology, Vol. 27, No. 4,
481-483 (1999)
DOI: 10.1177/019262339902700418
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Tryphonas and P.-G. Germann
Introduction and Summary of the Workshop "Drug Research Support: Selection and Early Development"
Toxicol Pathol,
January 1, 2002;
30(1):
2 - 3.
[PDF]
|
|
|
|
|
|
|
D. G. Robertson, M. D. Reily, R. E. Sigler, D. F. Wells, D. A. Paterson, and T. K. Braden
Metabonomics: Evaluation of Nuclear Magnetic Resonance (NMR) and Pattern Recognition Technology for Rapid in Vivo Screening of Liver and Kidney Toxicants
Toxicol. Sci.,
October 1, 2000;
57(2):
326 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
